Koers PledPharma AB (publ) Nasdaq Stockholm
Aandelen
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- SEK | - |
Omzet 2024 * | 60,73 mln. 5,69 mln. 5,25 mln. | Omzet 2025 * | 514 mln. 48,24 mln. 44,46 mln. | Marktkapitalisatie | 2,31 mld. 216 mln. 199 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -289 mln. -27,1 mln. -24,98 mln. | Nettowinst (verlies) 2025 * | 125 mln. 11,72 mln. 10,8 mln. | EV/omzet 2024 * | 35,2 x |
Nettoliquiditeiten 2024 * | 167 mln. 15,67 mln. 14,44 mln. | Nettoliquiditeiten 2025 * | 226 mln. 21,16 mln. 19,5 mln. | EV/omzet 2025 * | 4,04 x |
K/w-verhouding 2024 * |
-7,68
x | K/w-verhouding 2025 * |
14,6
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 54,24% |
Recentste transcriptie over PledPharma AB (publ)
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 48 | 16-06-17 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 45 | 31-12-17 |
Chief Tech/Sci/R&D Officer | - | 05-05-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Mats Blom
CHM | Chairman | 59 | 01-04-21 |
Director/Board Member | 50 | 01-01-20 | |
Thomas Lönngren
BRD | Director/Board Member | 73 | 01-04-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+12,30% | 118 mld. | |
+12,15% | 106 mld. | |
-8,14% | 23,4 mld. | |
-1,69% | 21,78 mld. | |
-10,60% | 18,09 mld. | |
-41,25% | 16,72 mld. | |
-15,33% | 15,97 mld. | |
+5,80% | 14,03 mld. | |
+28,03% | 11,67 mld. |
- Beurs
- Aandelen
- Koers EGTX
- Koers